S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NASDAQ:ZGNX

Zogenix - ZGNX Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$26.68
$26.68
50-Day Range
$26.10
$26.68
52-Week Range
$11.03
$26.90
Volume
94 shs
Average Volume
3.76 million shs
Market Capitalization
$1.50 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.50

Zogenix MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
34.0% Upside
$35.75 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-1.72
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.87) to ($1.17) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.80 out of 5 stars

Medical Sector

881st out of 1,098 stocks

Pharmaceutical Preparations Industry

431st out of 536 stocks

ZGNX stock logo

About Zogenix (NASDAQ:ZGNX) Stock

Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.

Receive ZGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zogenix and its competitors with MarketBeat's FREE daily newsletter.

ZGNX Stock News Headlines

Form POS AM ZOGENIX, INC. - StreetInsider.com
UCB Completes Acquisition of Zogenix, Inc.
Recap: Zogenix Q4 Earnings - Benzinga
Zogenix (ZGNX) Reports Q4 Loss, Tops Revenue Estimates
See More Headlines

Receive ZGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zogenix and its competitors with MarketBeat's FREE daily newsletter.

ZGNX Company Calendar

Last Earnings
11/04/2021
Today
8/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:ZGNX
CUSIP
98978L10
Employees
218
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$35.75
High Stock Price Forecast
$62.00
Low Stock Price Forecast
$23.00
Forecasted Upside/Downside
+29.3%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
7 Analysts

Profitability

Net Income
$-209,380,000.00
Net Margins
-278.38%
Pretax Margin
-278.26%

Debt

Sales & Book Value

Annual Sales
$81.69 million
Book Value
$6.64 per share

Miscellaneous

Free Float
53,922,000
Market Cap
$1.50 billion
Optionable
Optionable
Beta
0.89

Key Executives

  • Stephen James Farr
    President, Chief Executive Officer & Director
  • Ashish M. Sagrolikar
    Chief Operating Officer & Executive Vice President
  • Michael Patrick Smith
    Chief Financial Officer, Treasurer & Executive VP
  • Bradley S. Galer
    Chief Medical Officer & Executive Vice President
  • Steven A. Johnson
    Vice President, Legal Council & Compliance Office













ZGNX Stock - Frequently Asked Questions

Should I buy or sell Zogenix stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zogenix in the last twelve months. There are currently 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ZGNX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZGNX, but not buy additional shares or sell existing shares.
View ZGNX analyst ratings
or view top-rated stocks.

What is Zogenix's stock price forecast for 2022?

7 analysts have issued 12-month price objectives for Zogenix's shares. Their ZGNX share price forecasts range from $23.00 to $62.00. On average, they expect the company's share price to reach $35.75 in the next twelve months. This suggests a possible upside of 34.0% from the stock's current price.
View analysts price targets for ZGNX
or view top-rated stocks among Wall Street analysts.

How were Zogenix's earnings last quarter?

Zogenix, Inc. (NASDAQ:ZGNX) released its earnings results on Thursday, November, 4th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.96) by $0.08. The business had revenue of $22.61 million for the quarter, compared to analyst estimates of $22.71 million. Zogenix had a negative trailing twelve-month return on equity of 91.20% and a negative net margin of 278.38%. The company's quarterly revenue was up 690.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.02) EPS.

What is Stephen Farr, Ph.D.'s approval rating as Zogenix's CEO?

7 employees have rated Zogenix Chief Executive Officer Stephen Farr, Ph.D. on Glassdoor.com. Stephen Farr, Ph.D. has an approval rating of 85% among the company's employees.

What other stocks do shareholders of Zogenix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zogenix investors own include GW Pharmaceuticals (GWPH), Gilead Sciences (GILD), Vanda Pharmaceuticals (VNDA), AbbVie (ABBV), QUALCOMM (QCOM), Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Southwest Airlines (LUV) and Micron Technology (MU).

What is Zogenix's stock symbol?

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

What is Zogenix's stock price today?

One share of ZGNX stock can currently be purchased for approximately $26.68.

How much money does Zogenix make?

Zogenix (NASDAQ:ZGNX) has a market capitalization of $1.50 billion and generates $81.69 million in revenue each year. The company earns $-209,380,000.00 in net income (profit) each year or ($4.07) on an earnings per share basis.

How many employees does Zogenix have?

Zogenix employs 218 workers across the globe.

How can I contact Zogenix?

Zogenix's mailing address is 5959 Horton Street Suite 500, EMERYVILLE CA, 94608. The official website for the company is www.zogenix.com. The company can be reached via phone at (510) 550-8300, via email at ir@zogenix.com, or via fax at 858-259-1166.

This page (NASDAQ:ZGNX) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.